CMS-121 Powder

Description

Overview of CMS-121 Powder

CMS-121 is a synthetic quinoline derivative developed through chemical modification of fisetin, a naturally occurring flavonoid with known multitarget neuroprotective activity.

Researchers investigate CMS-121 powder for its potential role in cellular stressors, including ischemia, inflammation, and endogenous oxidative stress in research models.

CMS-121 is intended strictly for laboratory research purposes and is not approved for human or animal consumption.

Proposed Mechanism of Action of CMS-121 Powder

CMS-121 is a synthetic fisetin derivative that is being investigated for its effects on cellular metabolism and mitochondrial function in research models. 

Current research indicates that it primarily modulates fatty acid synthase (FASN), an enzyme involved in lipid biosynthesis, which may help reduce lipid peroxidation and oxidative stress. 

Studies also suggest that CMS-121 supports mitochondrial bioenergetics by preserving mitochondrial integrity and maintaining cellular redox balance. 

Rather than acting through a single molecular target, CMS-121 appears to regulate multiple pathways associated with lipid metabolism, oxidative stress, and mitochondrial homeostasis, making it an active area of research in cellular and molecular biology.

Chemical & Molecular Properties

Property	Description
Common Name	CMS-121 (CMS121)
Chemical Classification	Substituted quinoline; fisetin derivative
Molecular Formula	C₂₀H₁₉NO₃
Molecular Weight	321.37 g/mol
CAS Number	1353224-53-9
InChIKey	OMHNVUCFPJJLKD-UHFFFAOYSA-N
SMILES	Oc1ccc(-c2cc(OC3CCCC3)c3ccccc3n2)cc1O
Molecular Target	Acetyl-CoA carboxylase 1 (ACC1); fatty acid synthase (FASN)
Storage Condition	-20°C
Purity (Reference Grade)	≥98%
Analytical Characterization	HPLC, NMR spectroscopy

Potential Research Applications of CMS-121 Powder

Researchers investigate CMS-121 powder under controlled laboratory conditions for the following research applications. Though more extensive study is required.

• Lipid Peroxidation and Ferroptosis/Oxytosis Research

Used to study FASN-mediated lipid metabolism and its relationship to oxidative cell death pathways.

• Acetyl-CoA and Mitochondrial Metabolism Research

Investigated for effects on ACC1 phosphorylation and acetyl-CoA regulation in research models.

• Neuroinflammation Research

Used to examine microglial activation suppression in LPS-stimulated N9 cell models.

Why Choose Purerawz to Buy CMC-121 Powder?

Each batch of CMS-121 supplied by Purerawz undergoes first- and third-party testing, with a Certificate of Analysis (CoA) available for identity and purity verification. Purerawz maintains a 99%+ purity standard confirmed through independent batch testing.

Frequently Asked Questions

Why does CMS-121 have two different EC50 values?

Because iodoacetic acid and glutamate induce cell death through different upstream mechanisms (ischemia-mimicking metabolic stress vs. oxytosis via glutathione depletion), the differing potency suggests CMS-121 may intervene more efficiently at one stage of the stress-response cascade than another.

How can a single compound show both FASN-related and ACC1-related mechanistic data?

ACC1 and FASN operate sequentially in the same fatty acid synthesis pathway, so findings on ACC1 phosphorylation and FASN inhibition are describing two points along one connected metabolic pathway, not two unrelated mechanisms.

What does an 82% reduction in LPS-induced microglial activation actually tell researchers, mechanistically?

It indicates a substantial but incomplete suppression of the inflammatory response, which is useful for researchers benchmarking CMS-121's anti-inflammatory potency against complete inhibitors..

Disclaimer: 

The products sold by Purerawz are intended solely for laboratory and research purposes. They are not FDA-approved for human or animal consumption, and Purerawz does not sell these compounds for use in humans or animals. All compounds are strictly for use by qualified researchers in controlled, non-clinical laboratory environments in compliance with applicable regulations.

Reference Links

Chiruta, C., Schubert, D., Dargusch, R., & Maher, P. (2012). Chemical modification of the multitarget neuroprotective compound fisetin. Journal of Medicinal Chemistry, 55(1), 378–389. https://doi.org/10.1021/jm2012563

Prior, M., Dargusch, R., Ehren, J. L., Chiruta, C., & Schubert, D. (2014). Back to the future with phenotypic screening. ACS Chemical Neuroscience, 5(7), 503–513. https://doi.org/10.1021/cn500051h

Currais, A., Huang, L., Goldberg, J., Petrascheck, M., Ates, G., Pinto-Duarte, A., Shokhirev, M. N., Schubert, D., & Maher, P. (2019). Elevating acetyl-CoA levels reduces aspects of brain aging. eLife, 8, e47866. https://doi.org/10.7554/eLife.47866

Ates, G., Goldberg, J., Currais, A., & Maher, P. (2020). CMS121, a fatty acid synthase inhibitor, protects against excess lipid peroxidation and inflammation and alleviates cognitive loss in a transgenic mouse model of Alzheimer's disease. Redox Biology, 36, Article 101648. https://doi.org/10.1016/j.redox.2020.101648

Goldberg, J., Currais, A., Ates, G., Huang, L., Shokhirev, M., Maher, P., & Schubert, D. (2020). The mitochondrial ATP synthase is a shared drug target for aging and dementia. Aging Cell, 17(2), e12715. https://doi.org/10.1111/acel.12715